Review Article

An Evidence-Based Review of Related Metabolites and Metabolic Network Research on Cerebral Ischemia

Mengting Liu, Liying Tang, Xin Liu, Jing Fang, Hao Zhan, Hongwei Wu, and Hongjun Yang

Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China

Correspondence should be addressed to Hongwei Wu; whw9905012@163.com and Hongjun Yang; hongjun0420@vip.sina.com

Received 30 November 2015; Revised 27 March 2016; Accepted 14 April 2016

Academic Editor: Sayuri Miyamoto

Copyright © 2016 Mengting Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In recent years, metabolomics analyses have been widely applied to cerebral ischemia research. This paper introduces the latest proceedings of metabolomics research on cerebral ischemia. The main techniques, models, animals, and biomarkers of cerebral ischemia will be discussed. With analysis help from the MBRole website and the KEGG database, the altered metabolites in rat cerebral ischemia were used for metabolic pathway enrichment analyses. Our results identify the main metabolic pathways that are related to cerebral ischemia and further construct a metabolic network. These results will provide useful information for elucidating the pathogenesis of cerebral ischemia, as well as the discovery of cerebral ischemia biomarkers.

1. Introduction

Cerebral ischemia is caused by insufficient blood and oxygen delivery to the brain, which manifests as cerebral death or partial necrosis of the brain. According to the World Health Organization (WHO), ischemia causes 5 million deaths and 5 million cases of irrecoverable disability globally each year (http://www.who.int/en/). Cerebral ischemia is difficult to cure and has a high relapse rate. The specific cause of ischemia is quite complex and the mechanism of pathogenesis remains unclear. Recently, the rapid development of systems biology in areas like genomics, transcriptomics, and proteomics has brought cerebral ischemia research to a new level.

Metabolomics, also called metabonomics, is based on qualitative and quantitative analyses of the end products in specific organisms or cells [1]. In 1970, E. C. Horning and M. G. Horning began to study metabolic profiles of metabolites in humans [2]. In 1982, van der Greef analyzed urine samples by gas chromatography-mass spectrometry (GC-MS) for the first time. This was followed by Nicholson's research that applied nuclear magnetic resonance (NMR) to analyze the metabolic profiles of plasma and urine samples [3–5]. Metabolomics research rapidly progressed during the mid-1990s, when Fiehn and Nicholson defined the concepts of metabolomics and metabonomics, respectively [6, 7]. Acting as a bridge between genotypes and phenotypes, metabolomics can determine comprehensive changes that happen in diseases by analyzing big data pools. Metabolomics studies can clarify specific mechanisms from a systematic perspective by revealing metabolic networks and biomarker groups. When compared to isolated single pathways or single biomarkers, the systemic data are more beneficial for elucidating the pathogenesis of complex diseases like cerebral ischemia [8].

Thus far, the pathogenesis of cerebral ischemia has been linked to energy metabolism, excitatory amino acid toxicity, reactive oxygen species (ROS), and inflammatory responses. These processes involve many kinds of metabolites, whose qualitative and quantitative expression is the focus of metabolomics. This paper introduces the analytical techniques and models used in metabolomics research on cerebral ischemia. Then, the biomarker metabolites in rat cerebral ischemia are summarized. Additionally, based on pathway enrichment analyses, we have successfully determined related metabolic pathways and constructed a metabolic network for rat cerebral ischemia. These novel analyses provide powerful references that clarify cerebral ischemia pathogenesis and reveal related biomarkers.
2. Techniques in Metabolomics Research

2.1. NMR. NMR is one of the most common techniques used in metabolomics research and has been used since the 1970s [9]. Compared to MS, NMR is a nondestructive test. When samples are difficult to obtain, like cerebrospinal fluid (CSF), digestive fluid, or seminal fluid, NMR is advantageous because it is reproducible, safe, and efficient with the samples. In addition, 1H-NMR can provide robust information on metabolites, and it is advantageous in determining unknown compound structures. However, because NMR is not as sensitive as MS, it is unable to detect molecules at low concentrations [10]. Presently, scientists have successfully applied NMR to construct metabolite profiles from rat tissues, plasma, and human body fluids of cerebral ischemia. Creation of these profiles has promoted research on related pathogenesis and on development of anticerebral ischemia drugs. Importantly, NMR is a powerful tool in the fields of drug toxicity prediction, disease diagnosis, and aging research [1, 11–13].

2.2. Chromatography-Coupled MS. GC-MS was the first technique applied to metabolomics research [5]. To use GC-MS for a metabolomics assay, the derivatization step is essential to process biofluid samples like blood and urine [14]. Since commercial structure databases are available for reference, GC-MS is highly advantageous in metabolite identification. In contrast to GC-MS, high-performance liquid chromatography-MS (HPLC-MS) and ultra-performance liquid chromatography-MS (UPLC-MS) techniques do not need the derivatization step. Because they can detect pleney compounds, HPLC-MS and UPLC-MS have become the key techniques used in untargeted and targeted metabolomics [15–17]. Additionally, UPLC use reduces the chromatography running time, making high-throughput analyses achievable [15, 16]. However, techniques for LC-MS are underdeveloped, and there are not comprehensive and unified MS databases for endogenous small molecules. So experience-based reasoning and alignment with standard data are needed to identify the structures of compounds. In addition, the capillary electrophoresis-MS (CE-MS) technique has a high peak capacity and better sensitivity, so it can also be successfully applied [10]. In current cerebral ischemia metabolomics research, LC-MS is the dominant approach used for analyzing plasma, brain tissue, and CSF samples.

3. Animals and Models in Cerebral Ischemia Metabolomics Research

Commonly used animals for cerebral ischemia metabolomics research include rats, mice, gerbils, rabbits, dogs, cats, monkeys, and pigs (Table 1). Among these, the rat is most frequently used. Since research on other animals is relatively rare, we chose to summarize biomarkers and conduct functional enrichment analyses from rat cerebral ischemia data. For models, middle cerebral artery occlusion (MCAO) is the most canonical and most common [18]. In the original MCAO model, the exact locations of round tips could not be directly observed. Also, because the round tips cause unexpected reactions that may increase noise signals, MCAO has to be continuously modified. In fact, Shmonin and his colleagues have developed 5 modified MCAO models. Based on the infarct areas and data stability, they selected stable models of permanent cerebral ischemia [19].

4. Biomarkers in Rat Cerebral Ischemia

Based on important articles published from 1992 to present, we summarized 120 significantly changed metabolites in cerebral ischemia. All metabolites were presented at supplementary table in Supplementary Material available online at http://dx.doi.org/10.1155/2016/9162074 with KEGG ID and the related detection information. They have been divided into the following 5 categories: amino acids, nucleic acids, neurotransmitters, lipids, and others (mainly organic acids). Sample includes plasma, serum, CSF, cortex, hippocampus, striatum, thalamus, midbrain, white matter, pineal body, and olfactory bulb. Of these tissues, plasma, serum, CSF, cortex, hippocampus, and striatum are relatively well studied, while the remaining samples are less studied.

4.1. Amino Acids. Table 2 lists 25 amino acids that change in cerebral ischemia. These were measured from plasma, serum, cortex, hippocampus, striatum, thalamus, and midbrain rat tissues. It has been reported that excitatory amino acids (EAA, including glutamic acid and aspartate) and glycine in brain tissues increased 1 hour after reperfusion following ischemia [20, 21]. Wang et al. observed increased levels of glutamic acid in serum and CSF at 24 hours after ischemia/reperfusion, while other amino acids like alanine dynamically decreased and then increased. Glycine and serine levels in CSF continued to decrease in the 6 hours after ischemia [22]. However, not all experiments indicated that excitatory amino acids increased after ischemia/reperfusion. Wang et al. reported that the level of aspartate remained stable at 12 hours after reperfusion, although glutamic acid increased. Other amino acids like leucine, isoleucine, valine, and glutamine were decreased in rat serum and brain extracts [21].

4.2. Nucleic Acids. 20 of the 120 cerebral ischemia biomarkers are nucleic acids (Table 3). Irie et al. used LC-MS and matrix-assisted laser desorption/ionization-MS (MALDI-MS) techniques to detect 20 nucleic acids in rat cortex, hippocampus, and striatum after reperfusion and compared the results to a normal hemisphere. In cortex and striatum, most nucleic acid levels changed significantly, while levels in the hippocampus remained unchanged. Most nucleic acids, except AMP, constantly decreased during the long time period after reperfusion [23]. Two theories have been proposed to explain these decreases. First, during the early stage of ischemia, the robust synthesis process of excitatory amino acids quickly depletes the nucleic acid pool [24]. Second, the activity of ribose 5-phosphate dehydrogenase, which participates in the pentose phosphate pathway, decreases in ischemia, reducing the total nucleic acid level [25]. Increased AMP levels induce phosphorylation of AMP-activated protein kinase (AMPK), a kinase activated by AMP, further activating...
| Model                          | Animal          | Feature                                                                                                                                                                                                 | Reference |
|-------------------------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Global cerebral ischemia      |                 |                                                                                                                                                                                                       |           |
| Two-vessel occlusion (2VO)    | Rat             | High success rate, obviously damaged after ischemia/reperfusion; inducing whole-body hypotension in model preparation; influencing blood supply of other organs; it cannot be prepared in awake state, so neurobehavior assessment is infeasible | [64, 65] |
| Three-vessel occlusion (3VO)  | Rat             | Rapidly and effectively triggering ischemia; quickly recovering after reperfusion; suitable for acute whole-brained ischemia case, severe operation wound | [66, 67] |
| Four-vessel occlusion (4VO)   | Rat, rabbit     | Suitable for subacute case; it can operate in both anesthetized and awake states; reperfusion is feasible; high mortality rate of animals                                                             | [68]     |
| Focal cerebral ischemia       |                 |                                                                                                                                                                                                       |           |
| Craniotomy method             | Rat, mouse, cat, dog, pig | Accurate and reliable, consistent experimental conditions, high success rate, severe surgical damage; it cannot apply reperfusion, intracranial pressure increase in surgery, damage of blood-brain barrier, change of brain temperature Imitating in situ cerebral ischemia; it can evaluate the efficacy of thrombolytic agents, three types including microemboli suspension, single embolus, and multiemboli model | [69–73] |
| Thromboembolic model          | Rat, mouse      | Using artificial materials to replace natural clot to avoid self-thrombolysis; the volume of embolus is adjustable and able to totally block the target artery, reduce the influence of uncontrollable reperfusion, and precisely control the time point of ischemia/reperfusion and may cause inflammatory response | [69, 74–76] |
| Nonclot embolic model         | Rat, mouse, monkey | Well-reproducible, precise site of damage, precisely controllable time of ischemia; the operation of filament insertion into cranium cannot be directly observed and may cause hemorrhage and/or vasospasm | [77–79] |
| Intraluminal suture model     | Rat, mouse      | Chemicals stimulate the vessels and induce vasoconstriction or directly produce clots                                                                                                                    | [80–82] |
| Chemical induction model      | Rat, mouse      |                                                                                                                                                                                                       | [83–86] |
4.3. Neurotransmitters. 16 species of neurotransmitter biomarkers in rat cerebral ischemia have been detected in all areas of the brain (Table 4). Neurotransmitters can be divided into two groups: amino acid neurotransmitters and monoamine neurotransmitters. In the amino acid group, glutamate and aspartate are important excitatory neurotransmitters in brain CNS, while GABA and glycine are major inhibitory neurotransmitters. Taurine and serine can inhibit glutamate and GABA receptors. In previous studies, the observed results from amino acid neurotransmitters are not consistent. For example, taurine has been observed to decrease in ischemic tissues like cortex, hippocampus, and whole brain tissue; yet another research has found increased taurine levels in the hippocampus after ischemia [27–29].

In the monoamine group, the testing area and time after ischemia influence the results. In extracellular fluids, the levels of dopamine (DA), norepinephrine (NE), and serotonin (5-HT) increase after ischemia but quickly decrease after reperfusion. DA was increased at 30 minutes after ischemia in rat striatum [30]. DA and 5-HT release were significantly increased at 10 minutes after ischemia in rat nucleus accumbens [31]. However, the DA release was decreased in the nucleus accumbens and cortex of rat bilateral vertebral arteries [32]. Monoamines like DA, NE, and 5-HT do not share the same behavior changes in different cerebral areas, but they are related to free radical production, excitatory cellular toxicity, and cell death [33].

4.4. Lipids. Lipid metabolites for cerebral ischemia are very important and getting more attention. MALDI-MS imaging was used to visualize the spatial distribution and concentrations of sulfatide (d18:1-C24h:0), phosphatidylcholine (PCs), and LysoPCs within brain slices of MCAO rats [34, 35]. In clinical metabolomics research, the following six free lipids in CSF were significantly increased: myristic acid, docosahexaenoic acid (DHA), arachidonic acid, linoleic acid, palmitic acid, and oleic acid. Of these, arachidonic acid levels are the most important and are often used as biomarkers of cerebral ischemia.

---

**Table 2: Amino acids metabolites in cerebral ischemia.**

| Metabolites            | Plasma | Serum | CSF | Cortex | Hippocampus | Striatum | Thalamus | Midbrain | Whole brain tissue | Reference |
|------------------------|--------|-------|-----|--------|-------------|----------|----------|----------|--------------------|-----------|
| Tyrosine               | ✓      |       | ✓   | ✓      |             |          |          |          |                    | [20, 22, 23] |
| Serine                 | ✓      | ✓     |     |        |             |          |          |          |                    | [50]      |
| Dopamine               |        | ✓     | ✓   | ✓      | ✓           | ✓        |          |          |                    | [20, 22, 23, 50, 51, 55] |
| Alanine                | ✓      | ✓     | ✓   | ✓      | ✓           | ✓        |          |          |                    | [20, 22, 23, 27] |
| Citrulline             |        | ✓     |     |        |             |          |          |          |                    | [23]      |
| Methionine             |        | ✓     |     |        |             |          |          |          |                    | [20]      |
| γ-Aminobutyric acid (GABA) |     | ✓     | ✓   | ✓      | ✓           | ✓        |          |          |                    | [23, 27, 28, 55] |
| Threonine              |        |       | ✓   | ✓      |             |          |          |          |                    | [50]      |
| Glutamate              | ✓      | ✓     | ✓   | ✓      |             |          |          |          |                    | [21, 23, 27, 52, 55] |
| Valine                 | ✓      | ✓     | ✓   | ✓      |             |          |          |          |                    | [21, 50]  |
| Tryptophan             | ✓      | ✓     | ✓   | ✓      |             |          |          |          |                    | [20, 23]  |
| Serotonin              |        | ✓     | ✓   | ✓      | ✓           | ✓        | ✓        | ✓        |                    | [51]      |
| Glycine                | ✓      | ✓     | ✓   | ✓      |             |          |          |          |                    | [22, 28, 50] |
| Phenylalanine          | ✓      | ✓     | ✓   | ✓      |             |          |          |          |                    | [21, 23]  |
| Glutamine              |        | ✓     |     |        | ✓           | ✓        |          |          |                    | [23, 27, 28, 55, 87] |
| Glutamic acid          | ✓      | ✓     | ✓   | ✓      |             |          |          |          |                    | [20–22, 50] |
| Histidine              |        | ✓     | ✓   | ✓      |             |          |          |          |                    | [23]      |
| Aspartate              | ✓      | ✓     | ✓   | ✓      |             |          |          |          |                    | [20, 23, 27, 52] |
| Isoleucine             | ✓      | ✓     | ✓   | ✓      |             |          |          |          |                    | [21]      |
| Leucine                | ✓      | ✓     |     |        |             |          |          |          |                    | [21]      |
| Nicotinuric acid       | ✓      | ✓     |     |        |             |          |          |          |                    | [21]      |
| Homocysteine           |        |       | ✓   | ✓      |             |          |          |          |                    | [27]      |
| Lysine                 |        |       |     |        |             |          |          |          |                    | [20]      |
| Ornithine              | ✓      | ✓     |     |        |             |          |          |          |                    | [50]      |
| Arginine               |        |       | ✓   | ✓      |             |          |          |          |                    | [50]      |

phosphofructokinase-2 (PFK-2). In cells that lack oxygen, the PFK-2 activation induces a new round of damage [26].
Table 3: Nucleic acids metabolites in cerebral ischemia.

| Metabolites       | Cortex | Striatum | Whole brain tissue | Reference |
|-------------------|--------|----------|--------------------|-----------|
| UMP               | √      | √        | √                  | [23]      |
| UDP               | √      | √        | √                  | [23, 27]  |
| UDP-glucose       | √      | √        | √                  | [23]      |
| UTP               |        |          | √                  | [27]      |
| Uridine           | √      | √        | √                  | [23]      |
| Uric acid         | √      |          | √                  | [23, 27]  |
| Guanosine         | √      |          | √                  | [23]      |
| GMP               | √      |          | √                  | [23]      |
| Cytidine          | √      |          | √                  | [23]      |
| CDP-choline       | √      |          | √                  | [23]      |
| CMP               | √      |          | √                  | [23]      |
| ATP               | √      | √        | √                  | [23]      |
| AMP               | √      |          | √                  | [23]      |
| ADP               | √      |          | √                  | [23]      |
| Ribose 5-phosphate| √      | √        | √                  | [23]      |
| Neu5Ac            | √      |          | √                  | [23]      |
| Xanthine          | √      |          | √                  | [23, 27]  |
| Pseudouridine     | √      | √        | √                  | [23]      |
| PE                | √      |          | √                  | [23]      |
| PEP               | √      |          | √                  | [23]      |

UMP: uridine monophosphate; UDP: uridine diphosphate; UTP: uridine-5'-triphosphate; GMP: guanosine 5'-phosphate; CDP-choline: cytidine 5'-diphosphocholine; CMP: cytidine-5'-monophosphate; ATP: adenosine 5'-triphosphate; AMP: adenosine 5'-monophosphate; ADP: adenosine 5'-diphosphate; Neu5Ac: N-acetylneuraminate; PE: phosphoethanolamine; PEP: phosphoenolpyruvate.

changed most significantly. These results indicated that cerebral ischemia was related to the metabolism of arachidonic acid and DHA, as well as phospholipase activation [36]. It was also reported that, in the first few minutes after ischemia, monounsaturated fatty acids (MUFAs) began to accumulate and continued to increase over hours and days. Furthermore, there was a particularly high increase of MUFAs in the CA1 area of the hippocampus [37–43]. A similar result of increasing abundance of LPC 16:0, LPC 18:0, LPC 18:1, PC 34:0, PC 36:1, and PC 40:6 was stated by MALDI-MS profiling research [35]. Similar to MUFAs, some polyunsaturated fatty acids (PUFAs) like leukotriene C4 and prostaglandin E2 have a fast increase in early periods of ischemia/reperfusion [44]. In addition to mediating multiple important processes in cerebral ischemia, lipids are also involved in the development of Alzheimer’s disease (AD), Parkinson’s disease (PD), and Niemann-Pick disease [45, 46]. Currently, lipidomics and sterolomics have been used in AD research, independent of metabolomics [47]. Lipidomics is a powerful technique that can also be applied in cerebral ischemia research [48, 49].

4.5. Other Metabolites. 52 of the 120 metabolites altered in cerebral ischemia are basic metabolites from many important basal metabolic pathways (Table 5). Most of these basic metabolites are organic acids. Some examples are succinate, citrate, malate, cis-aconitic acid, and malonic acid, all of which are TCA pathway intermediates. Wang et al. detected citrate and malonic acid accumulation in serum at 0.5 and 3 hours after ischemia, while succinate levels decreased at 24 hours after ischemia [50]. Similar to Wang et al., Irie et al. detected citrate, malate, and cis-aconitic acid accumulation in striatum at 3 hours after ischemia [23]. A satisfying explanation for this is that some TCA-related enzymes likeaconitase and oxoglutarate dehydrogenase are inhibited, causing cycle suppression and subsequent intermediate accumulation (except succinate) [47]. As for lactate and pyruvate, they are significantly increased after ischemia, indicating that local cerebral ischemia enhances anaerobic metabolism [22, 27, 29, 39, 51–53].

Many basic metabolites, such as UDP, CDP-choline, glucose-6-phosphate (G6p), and UDP-Glucose, participate in biomembrane synthesis. After ischemia, these levels are reduced in cortex and in human acute lymphoblastic leukemia Jurkat cells, which is likely related to the cell membrane damage caused by ischemia [20, 34].

4.6. Summary. In early studies of cerebral ischemia, researchers usually prepared whole brain tissue homogenates. Results from these studies indicated the average level of metabolites in the whole brain. Unfortunately, the expression of individual metabolites in different cerebral areas is distinct [52, 54]. For instance, Macrì et al. found that alanine levels are reduced in the hippocampus and yet remain stable in the cortex [55]. Used as an index for ischemia evaluation, the ratio of choline to creatine changes differently in males and females and also in different cerebral areas [56–58]. Therefore, in cerebral ischemia metabolomics research, the influence of both spatial and temporal issues should be fully considered in biomarker discovery. Samples should be restricted to specific cerebral areas to ensure the accuracy of identified
Table 4: Neurotransmitter metabolites in cerebral ischemia.

| Metabolites                           | Plasma | Serum | CSF | Cortex | Hippocampus | Striatum | Thalamus + midbrain | White matter | Whole brain tissue | Reference |
|---------------------------------------|--------|-------|-----|--------|-------------|----------|---------------------|--------------|--------------------|-----------|
| Dopamine (DA)                         | ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [30–32, 51]|
| Norepinephrine (NE)                   | ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [51]      |
| Serotonin (5-HT)                      | ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [31, 32, 51]|
| 3-Methoxy-4-hydroxyphenylglycol (MHPG)| ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [51]      |
| 3,4-Dihydroxyphenylacetic acid (DOPAC)| ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [51]      |
| Homovanillic acid (HVA)               | ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [51]      |
| 5-Hydroxyindoleacetic acid (5-HIAA)   | ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [51]      |
| GABA                                  | ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [23, 27, 28, 55]|
| Glutamic acid                         | ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [20, 22, 28, 50]|
| Glycine                               | ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [22, 28, 50]|
| Glutamate                             | ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [21, 23, 27, 52, 55]|
| Aspartate                             | ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [20, 23, 27, 28]|
| Taurine                               | ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [27–29]   |
| Serine                                | ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [22, 50]  |
| Choline                               | ✓      | ✓     | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [27, 52, 54, 55, 88, 89]|
| γ-Hydroxybutyrate                     | ✓      |       | ✓   | ✓      |             | ✓        | ✓                   |              |                    | [53]      |
**TABLE 5: Other metabolites in cerebral ischemia.**

| Metabolites                                      | Plasma | Serum | CSF  | Cortex | Hippocampus | Striatum | White matter | Thalamus | Midbrain | Whole brain tissue | Pineal body, olfactory bulb | Reference |
|--------------------------------------------------|--------|-------|------|--------|-------------|----------|---------------|----------|----------|---------------------|---------------------------------|-----------|
| Choline phosphate                                | √      |       |      |        |             |          |               |          |          |                     |                                 | [23]      |
| Malate                                           |        | √     |      |        |             |          |               |          |          |                     |                                 | [23, 27] |
| Citrate                                          |        |       |      |        |             |          |               |          |          |                     |                                 | [23, 50]  |
| Succinate                                        |        | √     |      |        |             | √        |               |          |          |                     |                                 | [27]      |
| Creatinine                                       |        | √     |      |        |             |          |               |          |          |                     |                                 | [21, 22, 29] |
| 2-Hydroxybutyric acid                           |        | √     |      |        |             |          |               |          |          |                     |                                 | [22, 53]  |
| Creatine                                         |        |       |      |        |             |          |               |          |          |                     |                                 | [21, 22, 27] |
| Glutamate                                        |        | √     |      |        |             |          |               |          |          |                     |                                 | [21, 23, 27, 32, 54, 55] |
| cis-Aconitic acid                                |        |       |      |        |             |          |               |          |          |                     |                                 | [23]      |
| Malonate                                         |        |       |      |        |             |          |               |          |          |                     |                                 | [50]      |
| Alpha-D-glucose                                  |        |       |      |        |             |          |               |          |          |                     |                                 | [22, 27]  |
| Carnosine                                        |        |       |      |        |             |          |               |          |          |                     |                                 | [21]      |
| Nicotinamide adenine dinucleotide (NAD+)         |        | √     |      |        |             |          |               |          |          |                     |                                 | [23]      |
| N⁵-nitro-L-arginine methyl ester (L-NAME)         |        |       |      |        |             |          |               |          |          |                     |                                 | [23]      |
| N-Acetylaspartate (NAA)                          |        |       |      |        |             |          |               |          |          |                     |                                 | [23, 9]   |
| 6-Denoyl-6-[18F]fluoro-L-ascorbic acid           |        |       |      |        |             |          |               |          |          |                     |                                 | [51]      |
| 3-Methoxy-4-hydroxyphenylglycol (HMPG)           |        |       |      |        |             |          |               |          |          |                     |                                 | [23, 93]  |
| 3-Hydroxypropyl mercapturic acid                 |        |       |      |        |             |          |               |          |          |                     |                                 | [23]      |
| Glucosylphosphoric acid                         |        |       |      |        |             |          |               |          |          |                     |                                 | [23]      |
| Glutathione (GSH)                                |        |       |      |        |             |          |               |          |          |                     |                                 | [23, 24]  |
| Glutathione disulfide (GSSG)                     |        |       |      |        |             |          |               |          |          |                     |                                 | [23]      |
| Myo-inositol                                     |        |       |      |        |             |          |               |          |          |                     |                                 | [27, 54, 55] |
| Betaine                                          |        |       |      |        |             |          |               |          |          |                     |                                 | [50]      |
| Pyruvate                                         |        |       |      |        |             |          |               |          |          |                     |                                 | [22, 50]  |
| Lactate                                          |        |       |      |        |             |          |               |          |          |                     |                                 | [50, 52, 54, 55, 88] |
| 3,4-Dihydroxyphenylacetate (DOPAC)               |        |       |      |        |             |          |               |          |          |                     |                                 | [51]      |
| Homovanillic acid (HVA)                          |        |       |      |        |             |          |               |          |          |                     |                                 | [51]      |
| Nicotinuric acid                                 |        |       |      |        |             |          |               |          |          |                     |                                 | [23]      |
| Fumarate                                         |        |       |      |        |             |          |               |          |          |                     |                                 | [27]      |
| Glucose 6-phosphate                              |        |       |      |        |             |          |               |          |          |                     |                                 | [27]      |
| Formate                                          |        |       |      |        |             |          |               |          |          |                     |                                 | [27]      |
| Acetate                                          |        |       |      |        |             |          |               |          |          |                     |                                 | [23]      |
| Ascorbate                                        |        |       |      |        |             |          |               |          |          |                     |                                 | [23, 27, 28] |
| Taurine                                          |        |       |      |        |             |          |               |          |          |                     |                                 | [23, 27, 28] |
| Alpha-2-Ketoisovaleric acid                      |        |       |      |        |             |          |               |          |          |                     |                                 | [22]      |
| 3-Hydroxybutanoic acid                           |        |       |      |        |             |          |               |          |          |                     |                                 | [22]      |
| 3-Hydroxyisovalerate                             |        |       |      |        |             |          |               |          |          |                     |                                 | [22]      |
| Acetone                                          |        |       |      |        |             |          |               |          |          |                     |                                 | [22]      |
| Acetic acid                                      |        |       |      |        |             |          |               |          |          |                     |                                 | [22]      |
| Oxaloacetate                                     |        |       |      |        |             |          |               |          |          |                     |                                 | [22]      |
| Dimethylamine                                    |        |       |      |        |             |          |               |          |          |                     |                                 | [22]      |
| Glycerol                                         |        |       |      |        |             |          |               |          |          |                     |                                 | [22]      |
| D-Fructose                                       |        |       |      |        |             |          |               |          |          |                     |                                 | [22]      |
| Aminoguanidine                                   |        |       |      |        |             |          |               |          |          |                     |                                 | [23, 27, 28] |
| Polyamines                                       |        |       |      |        |             |          |               |          |          |                     |                                 | [23, 27, 28] |
| Putrescine                                       |        |       |      |        |             |          |               |          |          |                     |                                 | [34, 95]  |
| Spermidine                                       |        |       |      |        |             |          |               |          |          |                     |                                 | [34, 59]  |
| Spermine                                         |        |       |      |        |             |          |               |          |          |                     |                                 | [34, 59]  |
3. Spatial Localized Brain Tissue Metabolomics

In metabolomics research, the identification of metabolites is truly an arduous task. The existence of isomers, as well as overlapping peaks in NMR profiles, makes it difficult to identify specific compounds based on individual MS or NMR information [97]. For the MS technique, the present strategy is to upgrade the working resolution to improve compound composition accuracy and then verify the compounds by secondary-MS of the pyrolysate fragments. As for NMR, common strategies applied to identify complicated compounds include increasing the magnetic field intensity.
and use of multiple-nuclear NMR (1H, 13C, 15N, etc.) or multiple-dimension NMR editing (2D-COSY, NOESY, TOCSY, HSQC, etc.) [98–100]. The list of 120 currently known metabolites summarized in this paper provides an informative reference for quickly identifying cerebral ischemia metabolites.

Our explanation for the pathways found by functional enrichment analyses in cerebral ischemia will provide useful information for elucidating the pathogenesis of cerebral ischemia. The metabolic network we constructed will be useful in selecting molecular targets and clarifying the molecular mechanisms of cerebral ischemia. It should be noted that, due to the technical level of analytical instruments, current metabolomics technologies are not really global and not every metabolite can be accurately measured. In every piece of research, analytical instrument types, sample types, sampling time, and researcher skills all may influence the results of metabolomics study and the obtained biomarkers. So the enrichment analysis based on the metabolites from the literature will certainly have biases. However, up to now there are no papers summarizing the metabolic changes in cerebral ischemia nor any related databases. Our review will provide useful information for future research in this field.

Competing Interests

The authors declare that they have no competing interests.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (nos. 81330086, 81403210, and 81573726) and the Autonomic Project of China Academy of Chinese Medicine Sciences (nos. L2014063-Z221 and Z2013386-909).

References

[1] J. K. Nicholson, J. Connelly, J. C. Lindon, and E. Holmes, “Metabonomics: a platform for studying drug toxicity and gene function,” Nature Reviews Drug Discovery, vol. 1, no. 2, pp. 153–161, 2002.
[2] E. C. Horning and M. G. Horning, “Metabolic profiles: chromatographic methods for isolation and characterization of a variety of metabolites in man,” Methods in Medical Research, vol. 12, pp. 369–371, 1970.
[3] J. K. Nicholson, J. A. Timbrell, and P. J. Sadler, “Proton NMR spectra of urine as indicators of renal damage. Mercury-induced nephrotoxicity in rats,” Molecular Pharmacology, vol. 27, no. 6, pp. 644–651, 1985.
[4] J. K. Nicholson, M. J. Buckingham, and P. J. Sadler, “High resolution 1H n.m.r. studies of vertebrate blood and plasma,” Biochemical Journal, vol. 211, no. 3, pp. 605–615, 1983.
[5] J. van der Greef and D. C. Leegwater, “Urine profile analysis by field desorption mass spectrometry, a technique for detecting metabolites of xenobiotics. Application to 3,5-dinitro-2-hydroxytoluene,” Biomedical Mass Spectrometry, vol. 10, no. 1, pp. 1–4, 1983.
[6] O. Fiehn, “Metabolomics —the link between genotypes and phenotypes,” Plant Molecular Biology, vol. 48, no. 1-2, pp. 155–171, 2002.
[7] J. K. Nicholson, J. C. Lindon, and E. Holmes, “Metabonomics: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data,” Xenobiotica, vol. 29, no. 11, pp. 1181–1189, 1999.
[8] J. L. Griffin, H. Atherton, J. Shockcor, and L. Atzori, “Metabolomics as a tool for cardiac research,” Nature Reviews Cardiology, vol. 8, no. 11, pp. 630–643, 2011.
[9] F. F. Brown, I. D. Campbell, P. W. Kuchel, and D. C. Rabenstein, “Human erythrocyte metabolism studies by 1H spin echo NMR,” FEBS Letters, vol. 82, no. 1, pp. 12–16, 1977.
E. M. Lenz and I. D. Wilson, “Analytical strategies in metabolomics,” Journal of Proteome Research, vol. 6, no. 2, pp. 443–458, 2007.

D. Robertson, M. Reilly, J. Lindon, E. Holmes, and J. Nicholson, “Metabolomic technology as a tool for rapid throughput in vivo toxicity screening,” Comprehensive Toxicology, vol. 14, pp. 583–610, 2002.

M. E. Bollard, E. G. Stanley, J. C. Lindon, J. K. Nicholson, and E. Holmes, “NMR-based metabolomic approaches for evaluating physiological influences on biofluid composition,” NMR in Biomedicine, vol. 18, no. 3, pp. 143–162, 2005.

J. T. Brindle, H. Antti, E. Holmes et al., “Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabolomics,” Nature Medicine, vol. 8, no. 12, pp. 1439–1444, 2002.

T. Sangster, H. Major, R. Plumb, A. J. Wilson, and I. D. Wilson, “A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabolomic analysis,” Analyst, vol. 131, no. 10, pp. 1075–1078, 2006.

Q. Huang, P. Yin, J. Wang et al., “Method for liver tissue metabolic profiling study and its application in type 2 diabetic rats based on ultra performance liquid chromatography-mass spectrometry,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 879, no. 13-14, pp. 961–967, 2011.

P. Masson, A. C. Alves, T. M. D. Ebbels, J. K. Nicholson, and E. J. Want, “Optimization and evaluation of metabolite extraction protocols for targeted metabolic profiling of liver samples by UPLC-MS,” Analytical Chemistry, vol. 82, no. 18, pp. 7779–7786, 2010.

Q. Huang, Y. Tan, P. Yin et al., “Metabolic characterization of hepatocellular carcinoma using non-targeted tissue metabolomics,” Cancer Research, vol. 73, no. 16, pp. 4992–5002, 2013.

B. S. Allen, Y. Ko, G. D. Buckberg, S. Sakhai, and Z. Tan, “Studies of isolated global brain ischaemia: I. A new large animal model of global brain ischaemia and its baseline perfusion studies,” European Journal of Cardio-thoracic Surgery, vol. 41, no. 5, pp. 1138–1146, 2012.

A. Shmonin, E. Melnikova, M. Galagudza, and T. Vlasov, “Characteristics of cerebral ischemia in major rat stroke models of middle cerebral artery ligation through craniectomy,” International Journal of Stroke, vol. 9, no. 6, pp. 793–801, 2014.

J. Gao, H. Yang, J. Chen et al., “Analysis of serum metabolites for the discovery of amino acid biomarkers and the effect of galangin on cerebral ischemia,” Molecular Biosystems, vol. 9, no. 9, pp. 2311–2321, 2013.

W. T. Kimberly, Y. Wang, L. Pham, K. L. Furie, and R. E. Gerszten, “Metabolite profiling identifies a branched chain amino acid signature in acute cardioembolic stroke,” Stroke, vol. 44, no. 5, pp. 1389–1395, 2013.

Y. Wang, Y. Wang, M. Li et al., “1H NMR-based metabolomics exploring biomarkers in rat cerebrospinal fluid after cerebral ischemia/reperfusion,” Molecular BioSystems, vol. 9, no. 3, pp. 431–439, 2013.

M. Irie, Y. Fujimura, M. Yamato, D. Miura, and H. Warishii, “Integrated MALDI-MS imaging and LC-MS techniques for visualizing spatiotemporal metabolomic dynamics in a rat stroke model,” Metabolomics, vol. 10, no. 3, pp. 473–483, 2014.

S. Yousuf, F. Atif, M. Ahmad et al., “Resveratrol exerts its neuroprotective effect by modulating mitochondrial dysfunctions and associated cell death during cerebral ischemia,” Brain Research, vol. 1250, pp. 242–253, 2009.

S. Sarkar and N. Das, “Mannosylated liposomal flavonoid in combating age-related ischemia-reperfusion induced oxidative damage in rat brain,” Mechanisms of Ageing and Development, vol. 127, no. 4, pp. 391–397, 2006.

J. Li and L. D. McCullough, “Effects of AMP-activated protein kinase in cerebral ischemia,” Journal of Cerebral Blood Flow and Metabolism, vol. 30, no. 3, pp. 480–492, 2010.

M. Yang, S. Wang, F. Hao, Y. Li, H. Tang, and X. Shi, “NMR analysis of the rat neurochemical changes induced by middle cerebral artery occlusion,” Talanta, vol. 88, pp. 136–144, 2012.

H. Tang, Y. Tang, N. Li et al., “Neuroprotective effects of scutellarin and scutellarein on repeatedly cerebral ischemia-reperfusion in rats,” Pharmacology Biochemistry and Behavior, vol. 118, pp. 51–59, 2014.

P.-R. Wang, J.-S. Wang, M.-H. Yang, and L.-Y. Kong, “Neuroprotective effects of Huang-Lian-Jie-Du-Decoction on ischemic stroke rats revealed by 1H NMR metabolomics approach,” Journal of Pharmaceutical and Biomedical Analysis, vol. 88, pp. 106–116, 2014.

J. Gu, X.-R. He, and L.-P. Chen, “The protective effect of ginko biloba leaves injection on the brain dopamine in the rat model of cerebral ischemia/reperfusion injury,” African Health Sciences, vol. 14, no. 3, pp. 725–728, 2014.

K. Yoshimoto, M. Hori, N. Shinmen et al., “Forensic studies of brain vulnerability and resistance: ischemia-induced dopamine and serotonin releases in the rat nucleus accumbens,” Legal Medicine, vol. 11, supplement 1, pp. S279–S281, 2009.

K. Yoshimoto, A. Namera, Y. Arima et al., “Experimental studies of remarkable monoamine releases and neural resistance to the transient ischemia and reperfusion,” Pathophysiology, vol. 21, no. 4, pp. 309–316, 2014.

W.-W. Hu and Z. Chen, “Role of histamine and its receptors in cerebral ischemia,” ACS Chemical Neuroscience, vol. 3, no. 4, pp. 238–247, 2012.

D. Miura, Y. Fujimura, M. Yamato et al., “Ultrasensitive and in situ metabolic imaging for visualizing spatiotemporal metabolic behaviors,” Analytical Chemistry, vol. 82, no. 23, pp. 9789–9796, 2010.

H.-Y. J. Wang, H.-W. Wu, P.-J. Tsai, and C. B. Liu, “MALDI-mass spectrometry imaging of desalted rat brain sections reveals ischemia-mediated changes of lipids,” Analytical and Bioanalytical Chemistry, vol. 404, no. 1, pp. 113–124, 2012.

J. G. Piltis, W. M. Coplin, M. H. O’Regan et al., “Measurement of free fatty acids in cerebrospinal fluid from patients with hemorrhagic and ischemic stroke,” Brain Research, vol. 985, no. 2, pp. 198–201, 2003.

K. Abe, K. Kogure, H. Yamamoto, M. Imazawa, and K. Miyamoto, “Mechanism of arachidonic acid liberation during cerebral artery occlusion,” Journal of Neurochemistry, vol. 48, no. 2, pp. 503–509, 1987.

K. Abe, M. Yoshidomi, and K. Kogure, “Arachidonic acid metabolism in ischemic neuronal damage,” Annals of the New York Academy of Sciences, vol. 559, pp. 259–268, 1989.

N. G. Bazan Jr., “Effects of ischemia and electroconvulsive shock on free fatty acid pool in the brain,” Biochimica et Biophysica Acta (BBA)—Lipids and Lipid Metabolism, vol. 218, no. 1, pp. 1–10, 1970.
Oxidative Medicine and Cellular Longevity

[40] R. J. Gewirtz, H. S. Dhillon, S. E. Goes, S. M. DeAtley, and S. W. Scheff, "Lactate and free fatty acids after subarachnoid hemorrhage," *Brain Research*, vol. 840, no. 1-2, pp. 84–91, 1999.

[41] H. Yasuda, K. Kishiro, N. Izumi, and M. Nakanishi, "Biphasic liberation of arachidonic and stearic acids during cerebral ischemia," *Journal of Neurochemistry*, vol. 45, no. 1, pp. 168–172, 1985.

[42] S. Yoshida, S. Inoh, T. Asano et al., "Effect of transient ischemia on free fatty acids and phospholipids in the gerbil brain. Lipid peroxidation as a possible cause of postischemic injury," *Journal of Neurosurgery*, vol. 33, no. 3, pp. 323–331, 1980.

[43] Y. Katayama, T. Kawamata, T. Maeda, and T. Tsubokawa, "Free fatty acid liberation and cellular swelling during cerebral ischemia: the role of excitatory amino acids," *Acta Neurochirurgica Supplement*, vol. 60, pp. 242–245, 1994.

[44] H. F. Batirel, S. Aktan, C. Aykut, B. C. Ye˘gen, and T. Cos¸kun, "NatureReviews M.R.Wenk, "Theemerging field of lipidomics,"

[45] W. J. Griffiths, M. O. Ogundare, C. M. Williams, and Y. Wang, "On the future of 'omics': lipidomics," *Nature Reviews Drug Discovery*, vol. 4, no. 7, pp. 594–610, 2005.

[46] L. Tretter and V. Adam-Vizi, "Inhibition of Krebs cycle enzymes by hydrogen peroxide: a key role of [α]-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress," *The Journal of Neuroscience*, vol. 20, no. 24, pp. 8972–8979, 2000.

[47] R. M. Adibhatla, J. F. Hatcher, and R. J. Dempsey, "Lipids and lipidomics in brain injury and diseases," *AAPS Journal*, vol. 8, no. 2, pp. E314–E321, 2006.

[48] W. J. Griffiths, M. Ogundare, C. M. Williams, and Y. Wang, "On the future of 'omics': lipidomics," *Journal of Inherited Metabolic Disease*, vol. 34, no. 3, pp. 583–592, 2011.

[49] Y. Wang, Y. G. Wang, T. F. Ma, M. Li, and S. L. Gu, "Dynamic metabolites profile of cerebral ischemia/reperfusion revealed by 1H NMR-based metabolomics contributes to potential biomarkers," *International Journal of Clinical and Experimental Pathology*, vol. 7, no. 7, pp. 4067–4075, 2014.

[50] K.-I. Tanaka, N. Wada, and N. Ogawa, "Chronic cerebral hypoperfusion induces transient reversible monoamineergic changes in the rat brain," *Neurochemical Research*, vol. 25, no. 2, pp. 313–320, 2000.

[51] H. Widmer, H. Abiko, A. I. Faden, T. L. James, and P. R. Weinstein, "Effects of hyperglycemia on the time course of changes in energy metabolism and pH during global cerebral ischemia and reperfusion in rats: correlation of 1H and 31P NMR spectroscopy with fatty acid and excitatory amino acid levels," *Journal of Cerebral Blood Flow and Metabolism*, vol. 12, no. 3, pp. 456–468, 1992.

[52] B. Gao, E. Kilic, C. R. Baumann, D. M. Hermann, and C. L. Bassetti, "Gamma-hydroxybutyrate accelerates functional recovery after focal cerebral ischemia," *Cerebrovascular Diseases*, vol. 26, no. 4, pp. 413–419, 2008.

[53] T. Michaelis, M. Wick, H. Fujimori, A. Matsumura, and J. Frahm, "Proton MRS of oral creatine supplementation in rats, Cerebral metabolite concentrations and ischemic challenge," *NMR in Biomedicine*, vol. 12, no. 5, pp. 309–314, 1999.

[54] M. A. Macri, N. D'Alessandro, C. Di Giulio et al., "Regional changes in the metabolite profile after long-term hypoxia-ischemia in brains of young and aged rats: a quantitative proton MRS study," *Neurobiology of Aging*, vol. 27, no. 1, pp. 98–104, 2006.

[55] S. M. Manienga, V. Cvooro, P. A. Armitage, I. Marshall, M. E. Bastin, and J. M. Wardlaw, "Choline and creatine are not reliable denominators for calculating metabolite ratios in acute ischemic stroke," *Stroke*, vol. 39, no. 9, pp. 2467–2469, 2008.

[56] V. Cvooro, J. M. Wardlaw, I. Marshall et al., "Associations between diffusion and perfusion parameters, N-acetyl aspartate, and lactate in acute ischemic stroke," *Stroke*, vol. 40, no. 3, pp. 767–772, 2009.

[57] M. Lemesle, P. Walker, F. Guy et al., "Multi-variante analysis predicts clinical outcome 30 days after middle cerebral artery infarction," *Acta Neurologica Scandinavica*, vol. 102, no. 1, pp. 11–17, 2000.

[58] M. L. Reyzer and R. M. Capriolo, "MALDI-MS-based imaging of small molecules and proteins in tissues," *Current Opinion in Chemical Biology*, vol. 11, no. 1, pp. 29–35, 2007.

[59] M. Chagoyen and F. Pazos, "MBRole: enrichment analysis of metabolomic data," *Bioinformatics*, vol. 27, no. 5, Article ID biu001, pp. 730–731, 2011.

[60] B. Thomas and M. Flint Beal, "Parkinson’s disease," *Human Molecular Genetics*, vol. 16, no. 2, pp. R183–R194, 2007.

[61] T. Wallimann, M. Wyss, D. Brdiczka, K. Nicolay, and H. M. Eppenberger, "Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the ‘phosphocreatine circuit’ for cellular energy homeostasis," *Biochemical Journal*, vol. 281, no. 1, pp. 21–40, 1992.

[62] T. Wallimann, M. Tokarska-Schlattner, and U. Schlattner, "The creatine kinase system and pleiotropic effects of creatine," *Amino acids*, vol. 40, no. 5, pp. 1271–1296, 2011.

[63] D. Zhou, G. A. Matchett, V. Gadhav, N. Dach, and J. H. Zhang, "The effect of 2-methoxyestradiol, a HIF-1α inhibitor, in global cerebral ischemia in rats," *Neurological Research*, vol. 30, no. 3, pp. 268–271, 2008.

[64] Y. Yang, J. Zhang, H. Liu, and L. Zhang, "Change of Nrf2 expression in rat hippocampus in a model of chronic cerebral hypoperfusion," *International Journal of Neuroscience*, vol. 124, no. 8, pp. 577–584, 2014.

[65] J. C. de la Torre, T. Fortin, G. A. S. Park, B. A. Pappas, and M. T. Richard, "Brain blood flow restoration ‘rescues’ chronically damaged rat CA1 neurons," *Brain Research*, vol. 623, no. 1, pp. 6–15, 1993.

[66] H. Yanamoto, I. Nagata, Y. Niitsu, J.-H. Xue, Z. Zhang, and H. Kikuchi, "Evaluation of MCAO stroke models in normotensive rats: standardized neocortical infarction by the 3VO technique," *Experimental Neurology*, vol. 182, no. 2, pp. 261–274, 2003.

[67] W. A. Pulsinelli and J. B. Brierley, "A new model of bilateral hemispheric ischemia in the unanesthetized rat," *Stroke*, vol. 10, no. 3, pp. 267–272, 1979.

[68] J. B. Bederson, I. M. Germano, L. Guarino, and J. P. Muizelaar, "Cortical blood flow and cerebral perfusion pressure in a new noncraniotomy model of subarachnoid hemorrhage in the rat," *Stroke*, vol. 26, no. 6, pp. 1086–1092, 1995.

[69] R. L. Roof, G. P. Schielke, X. Ren, and E. D. Hall, "A comparison of long-term functional outcome after 2 middle cerebral artery occlusion models in rats," *Stroke*, vol. 32, no. 11, pp. 2648–2657, 2001.

[70] S. T. Bland, T. Schallert, R. Strong, J. Aronowski, and J. C. Grotta, "Early exclusive use of the affected forelimb after moderate transient focal ischemia in rats: functional and anatomic outcome," *Stroke*, vol. 31, no. 5, pp. 1144–1152, 2000.
[72] H. Nakano, B. O. Colli, and S. Lopes Lda, “Neuroprotective effect of mild hypothermia in the temporary brain ischemia in cats,” Anq Neuropsiquiatr, vol. 65, no. 3, pp. 810–815, 2007.

[73] H. Imai, K. Koniso, M. Nakamura et al., “A new model of focal cerebral ischemia in the miniature pig,” Journal of Neurosurgery, vol. 104, no. 2, supplement, pp. 123–132, 2006.

[74] M. Kudo, A. Aoyama, S. Ichimori, and N. Fukunaga, "An animal model of cerebral infarction. Homologous blood clot emboli in rats," Stroke, vol. 13, no. 4, pp. 505–514, 1982.

[75] C. Orset, R. Macrez, A. R. Young et al., "Mouse model of in situ thromboembolic stroke and reperfusion," Stroke, vol. 38, no. 10, pp. 2771–2778, 2007.

[76] K. Krueger and E. Busch, "Protocol of a thromboembolic stroke model in the rat: review of the experimental procedure and comparison of models," Investigative Radiology, vol. 37, no. 11, pp. 600–608, 2002.

[77] Y. Yoshida, T. Mikami, K. Higashi et al., "The profile of hippocampal metabolites differs between Alzheimer’s disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy," Journal of Cerebral Blood Flow and Metabolism, vol. 32, no. 5, pp. 805–815, 2012.

[78] D. Hesselbarth, C. Franke, R. Hata, G. Brinker, and M. Hoehn-Berlage, “High resolution MRI and MRS: a feasibility study for the investigation of focal cerebral ischemia in mice,” NMR in Biomedicine, vol. 11, pp. 423–429, 1998.

[79] K. P. J. Braun, P. van Eijsden, W. P. Vandertop et al., "Cerebral metabolism in experimental hydrocephalus: an in vivo $^1$H and $^3$P magnetic resonance spectroscopy study," Journal of Neurosurgery, vol. 91, no. 4, pp. 660–668, 1999.

[80] M. Shibata, N. Araki, J. Hamada, T. Sasaki, K. Shimazu, and Y. Fukuuchi, "Brain nitrite production during global ischemia and reperfusion: an in vivo microdialysis study," Brain Research, vol. 734, no. 1–2, pp. 86–90, 1996.

[81] J. Liu, R. A. Sheldon, M. R. Segal et al., "$^1$H nuclear magnetic resonance brain metabolomics in neonatal mice after hypoxia-ischemia distinguished normothermic recovery from mild hypothermia recoveries," Pediatric Research, vol. 74, no. 2, pp. 170–179, 2013.

[82] Y. Yoshida, T. Mikami, K. Higashi et al., "Inverse correlation between stroke and urinary 3-hydroxypropyl mercapturic acid, an acrolein-gluthathione metabolite," Clinica Chimica Acta, vol. 413, no. 7–8, pp. 753–759, 2012.

[83] K. M. Cockcroft, M. Meistrell III, G. A. Zimmerman et al., "Cerebroprotective effects of aminoguanidine in a rodent model of stroke," Stroke, vol. 27, no. 8, pp. 1393–1398, 1996.

[84] K. Takano, M. Ogura, Y. Nakamura, and Y. Inoda, "Neuronal and glial responses to polyanines in the ischemic brain," Current Neurovascular Research, vol. 2, no. 3, pp. 213–223, 2005.

[85] K. Ohki, H. Ooka, S. Iwayama, S. Kojima, and H. Yoneoka, "A new model of focal cerebral ischemia in rats and mice," Brain Research, vol. 931, no. 1–2, pp. 49–58, 2002.

[86] J. E. Want, P. Masson, F. Michopoulos et al., "Global metabolic profiling of animal and human tissues via UPLC-MS," Nature Protocols, vol. 8, no. 1, pp. 17–32, 2013.

[87] D. S. Wishart, "Quantitative metabolomics using NMR," TrAC Trends in Analytical Chemistry, vol. 27, no. 3, pp. 228–237, 2008.

[88] H. M. Parsons, C. Ludwig, U. L. Günter, and M. R. Viant, "Improved classification accuracy in 1- and 2-dimensional NMR metabolomics data using the variance stabilising generalised logarithm transformation," BMC Bioinformatics, vol. 8, article 234, 2007.